Unscientific and Unethical, Says US Expert as Chinese Pharma Pushes Wuhan Virus Vaccine Not Fully Tested
The Chinese pharmaceutical CanSino was reported to have been negotiating with several countries for urgent approval of the use of its Wuhan virus vaccine, which is still in phase 3 trials. Public health experts have voiced concerns as the vaccine has yet to be fully tested for its safety and effectiveness on a mass scale. They stressed that the experimentation and the trials must be transparent and that CanSino must disclose data concerning the vaccine’s trials in the Chinese military.
A senior manager at CanSino revealed to The Wall Street Journal that the pharma was negotiating with several countries, requesting emergency approval for the use of its experimental Wuhan virus vaccine before its phase 3 trials are completed. If approved, the early-stage vaccine will be in use globally for the first time, with health professionals and essential workers like soldiers and police officers being the first to get the shot.
Public health experts worry that despite the new evidence indicating the vaccine’s effectiveness and safety, it is highly risky to put it to public use before large-scale trials are completed. Dr Amesh A. Adalja, a senior expert at the John Hopkins Center for Health Security, said there is some data showing the vaccine’s effectiveness and safety following its trials in the Chinese military. “It is crucial, however, to use the vaccine in accordance with the data obtained at Phase 3 clinical trials,” he added. “Its effectiveness can be determined only in an environment where many people are exposed to the virus, and it is necessary to look into a better sample group to know if the vaccine is safe.” CanSino, he said, should disclose the data obtained at trials in the military to reassure the public.
Pierre Armand Morgon, Senior Vice President for International Business of CanSino, said giving several million people the vaccine before the clinical trials conclude helps ascertain its safety and effectiveness and create a database of safety information. Morgon declined to name all of the countries the pharma is in talks with, saying only that they include Pakistan, Latin American countries and a number of developed countries. None of them has approved the vaccine for use, he said.
Source: Apple Daily #Aug29
#China #CanSino #WuhanVirus #Coronavirus #COVID19 #Pandemic #Vaccine #Ethics
https://bit.ly/2RqheYn
The Chinese pharmaceutical CanSino was reported to have been negotiating with several countries for urgent approval of the use of its Wuhan virus vaccine, which is still in phase 3 trials. Public health experts have voiced concerns as the vaccine has yet to be fully tested for its safety and effectiveness on a mass scale. They stressed that the experimentation and the trials must be transparent and that CanSino must disclose data concerning the vaccine’s trials in the Chinese military.
A senior manager at CanSino revealed to The Wall Street Journal that the pharma was negotiating with several countries, requesting emergency approval for the use of its experimental Wuhan virus vaccine before its phase 3 trials are completed. If approved, the early-stage vaccine will be in use globally for the first time, with health professionals and essential workers like soldiers and police officers being the first to get the shot.
Public health experts worry that despite the new evidence indicating the vaccine’s effectiveness and safety, it is highly risky to put it to public use before large-scale trials are completed. Dr Amesh A. Adalja, a senior expert at the John Hopkins Center for Health Security, said there is some data showing the vaccine’s effectiveness and safety following its trials in the Chinese military. “It is crucial, however, to use the vaccine in accordance with the data obtained at Phase 3 clinical trials,” he added. “Its effectiveness can be determined only in an environment where many people are exposed to the virus, and it is necessary to look into a better sample group to know if the vaccine is safe.” CanSino, he said, should disclose the data obtained at trials in the military to reassure the public.
Pierre Armand Morgon, Senior Vice President for International Business of CanSino, said giving several million people the vaccine before the clinical trials conclude helps ascertain its safety and effectiveness and create a database of safety information. Morgon declined to name all of the countries the pharma is in talks with, saying only that they include Pakistan, Latin American countries and a number of developed countries. None of them has approved the vaccine for use, he said.
Source: Apple Daily #Aug29
#China #CanSino #WuhanVirus #Coronavirus #COVID19 #Pandemic #Vaccine #Ethics
https://bit.ly/2RqheYn